Overexpression of HER2 is observed in about 8-27 % gastric cancers. According to many authors, overexpression and/or amplification of HER2 correlates with poor prognosis. The aim of our study was to analyze HER2 expression in gastric cancer in material routinely examined in Pathomorphology Department, JUMC. Method: We have analyzed 50 cases of gastric cancers. The material came from 19 females and 31 males, age: 21-86. Immunohistochemical reactions were performed automatically on BenchMark BMK Classic (Ventana) using PATH-WAY HER-2/neu (4B5) antibody. Scoring system for HER2 expression was ranged from 0 to 3+ where: 0 and 1+ were regarded as a negative, 2+ as equivocal and 3+ as positive.